[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
create a website
Prescription Drug Insurance and Reimbursement. (2012). Grootendorst, Paul .
In: Chapters.
RePEc:elg:eechap:14021_11.

Full description at Econpapers || Download paper

Cited: 1

Citations received by this document

Cites: 48

References cited by this document

Cocites: 23

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. Pharmaceutical regulation and health policy objectives. (2013). Birg, Laura.
    In: Center for European, Governance and Economic Development Research Discussion Papers.
    RePEc:zbw:cegedp:183.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Aaserud, M., A.T. Dahlgren, J.P. Kösters, A.D. Oxman, C. Ramsay and H. Sturm (2006), ‘Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies’, Cochrane Database Systematic Reviews, 2, CD005979.
    Paper not yet in RePEc: Add citation now
  2. Abelson, R. and N. Singer (2010), ‘Pharmacists take larger role on health team’, New York Times, 13 August, available at: http://www.nytimes.com/2010/08/14/health/14pharmacist.html Acemoglu, D. and J. Linn (2004), ‘Market size in innovation: theory and evidence from the pharmaceutical industry’, Quarterly Journal of Economics, 119 (3), 1049–90.
    Paper not yet in RePEc: Add citation now

  3. Alan, S., T.F. Crossley, P. Grootendorst and M.R. Veall (2002), ‘The effects of drug subsidies on out-of-pocket M2835 - JONES 9781849802673 PRINT.indd 120 M2835 - JONES 9781849802673 PRINT.indd 120 04/01/2012 13:06 04/01/2012 13:06 Andrew M. Jones - 9781849802673 Downloaded from Elgar Online at 10/05/2016 07:36:51PM via CitEc (NOT FOR DISTRIBUTION, SHARING or POSTING) Prescription drug insurance and reimbursement 121 prescription drug expenditures by seniors: regional evidence from Canada’, Journal of Health Economics, 21 (5), 805–26.

  4. Alan, S., T.F. Crossley, P. Grootendorst and M.R. Veall (2005), ‘Distributional effects of general population prescription drug programs in Canada’, Canadian Journal of Economics, 38 (1), 128–48.

  5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002), ‘Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT)’, Journal of the American Medical Association, 288 (23), 2981–97.
    Paper not yet in RePEc: Add citation now
  6. Anis, A.H., L.D. Lynd, X. Wang, G. King, J.J. Spinelli, M. Fitzgerald and T. Bai (2001), ‘Double trouble: impact of inappropriate use of asthma medication on the use of health care resources’, Canadian Medical Association Journal, 164 (5), 625–31.
    Paper not yet in RePEc: Add citation now

  7. Berndt, E.R. (2002), ‘Pharmaceuticals in US health care: determinants of quantity and price’, Journal of Economic Perspectives, 16, 45–66.

  8. Blais, L., A. Castilloux, J. Couture and J. LeLorier (1999), ‘Impact of the Quebec cost sharing drug plan on asthmatic patients receiving social assistance’, Canadian Journal of Clinical Pharmacology, 6 (1), 42.
    Paper not yet in RePEc: Add citation now

  9. Blume-Kohout M.E. and N. Sood (2008), ‘The impact of Medicare Part D on pharmaceutical R&D’, NBER Working Paper, 13857.

  10. Cawley, J. and T. Philipson (1999), ‘An empirical examination of information barriers to trade in insurance’, American Economic Review, 89 (4), 827–46.

  11. Chernew, M.E., A.B. Rosen and A.M. Fendrick (2007), ‘Value based insurance design’, Health Affairs, 26 (2), w195–w203.
    Paper not yet in RePEc: Add citation now
  12. Commonwealth of Australia (1995), Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Major Submissions Involving Economic Analyses, Canberra: Australian Government Publishing Service.
    Paper not yet in RePEc: Add citation now

  13. Contoyannis, P., J. Hurley, P. Grootendorst, S. Jeon and R. Tamblyn (2005), ‘Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada’, Health Economics, 14 (9), 909–23.

  14. Ellis, R. (1986), ‘Rational behavior in the presence of coverage ceilings and deductibles’, The Rand Journal of Economics, 17 (2), 158–75.

  15. Engelhardt G.V. and J. Gruber (2010), ‘Medicare Part D and the financial protection of the elderly’, NBER Working Paper, 16155.
    Paper not yet in RePEc: Add citation now
  16. Evans, R.G. (1984), ‘Strained mercy: the economics of Canadian health care’, available at http://www.chspr.
    Paper not yet in RePEc: Add citation now

  17. Finkelstein, A. (2002), ‘The effect of tax subsidies to employer-provided supplementary health insurance: evidence from Canada’, Journal of Public Economics, 84 (3), 305–39.

  18. Finkelstein, A. (2004), ‘Static and dynamic effects of health policy: evidence from the vaccine industry’, Quarterly Journal of Economics, 119, 527–64.
    Paper not yet in RePEc: Add citation now
  19. Fischer, M.A., S. Schneeweiss, J. Avorn and D.H. Solomon (2004), ‘Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors’, The New England Journal of Medicine, 351 (21), 2187–94.
    Paper not yet in RePEc: Add citation now
  20. Gemmill M.C., S. Thomson and E. Mossialos (2008), ‘What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries’, International Journal for Equity in Health, 7 (12), doi:10.1186/1475-9276-7-12, available at http://www.equityhealthj.com/content/7/1/12 (accessed 9 September 2010).
    Paper not yet in RePEc: Add citation now
  21. Gleason, P., B.W. Gunderson and K.R. Gericke (2005), ‘Are incentive-based formularies inversely associated with drug utilization in managed care?’, The Annals of Pharmacotherapy, 39 (2), 339–45.
    Paper not yet in RePEc: Add citation now
  22. Goldman D.P., G.F. Joyce and Y. Zheng (2007), ‘Prescription drug cost sharing: associations with medication and medical utilization and spending and health’, JAMA, 298, 61–9.
    Paper not yet in RePEc: Add citation now
  23. Green, C.J., M. Maclure, P.M. Fortin, C.R. Ramsay, M. Aaserud and S. Bardal (2010), ‘Pharmaceutical policies: effects of restrictions on reimbursement’, Cochrane Database Systematic Reviews, 8, CD008654.
    Paper not yet in RePEc: Add citation now
  24. Grootendorst, P. (2005), ‘The impact of an on-line pharmacy claims adjudication network on use and costs of prescription drugs: evidence from British Columbia Pharmacare’, Journal of Pharmaceutical Finance, Economics & Policy, 13 (3), 27–39.
    Paper not yet in RePEc: Add citation now

  25. Grootendorst, P., A. Hollis, D.K. Levine. T. Pogge and A.M. Edwards (2011), ‘New approaches to rewarding pharmaceutical innovation’, Canadian Medical Association Journal, 183, 681–5.

  26. Lakdawalla D. and N. Sood (2009), ‘Innovation and the welfare effects of public drug insurance’, Journal of Public Economics, 93, 541–48.

  27. Lexchin, J. and P. Grootendorst (2004), ‘Effects of prescription drug user fees on drug and health services use M2835 - JONES 9781849802673 PRINT.indd 121 M2835 - JONES 9781849802673 PRINT.indd 121 04/01/2012 13:06 04/01/2012 13:06 Andrew M. Jones - 9781849802673 Downloaded from Elgar Online at 10/05/2016 07:36:51PM via CitEc (NOT FOR DISTRIBUTION, SHARING or POSTING) The Elgar companion to health economics, second edition and on health status in vulnerable populations: a systematic review of the evidence’, International Journal of Health Services, 34 (1), 101–22.

  28. Lexchin, Joel (2002), ‘Effects of restrictive formularies in the ambulatory care setting’, The American Journal of Managed Care, 8 (1), 69–74.
    Paper not yet in RePEc: Add citation now
  29. Lichtenberg F.R. and J. Waldfogel (2009), ‘Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act’, Michigan Telecommunications Technology Law Review, 15, 335–57, available at: http://www.mttlr.org/volfifteen/lichtenberg&waldfogel.pdf (accessed 22 April 2010).
    Paper not yet in RePEc: Add citation now
  30. Lichtenberg, F. and S. Sun (2007), ‘The impact of Medicare Part D on prescription drug use by the elderly’, Health Affairs, 26, 1735–744.
    Paper not yet in RePEc: Add citation now
  31. M2835 - JONES 9781849802673 PRINT.indd 122 M2835 - JONES 9781849802673 PRINT.indd 122 04/01/2012 13:06 04/01/2012 13:06 Andrew M. Jones - 9781849802673 Downloaded from Elgar Online at 10/05/2016 07:36:51PM via CitEc (NOT FOR DISTRIBUTION, SHARING or POSTING)
    Paper not yet in RePEc: Add citation now
  32. Morgan S., K.L. Bassett, J.M. Wright and L. Yan (2005), ‘First-line first? Trends in Thiazide prescribing for hypertensive seniors’, PLoS Medicine, 2 (4), e80. doi:10.1371/journal.pmed.0020080.
    Paper not yet in RePEc: Add citation now
  33. Morgan, S. (2004), ‘Drug spending in Canada: recent trends and causes’, Medical Care, 42 (7), 635–42.
    Paper not yet in RePEc: Add citation now
  34. Oxman, A.D., M.A. Thomson, D.A. Davis and B. Haynes (1995), ‘No magic bullets: a systematic review of 102 trials of interventions to improve professional practice’, Canadian Medical Association Journal, 153 (10), 1423–31.
    Paper not yet in RePEc: Add citation now
  35. Pauly, M.V. (1968), ‘The economics of moral hazard: comment’, American Economic Review, 58 (3), 531–37.
    Paper not yet in RePEc: Add citation now

  36. Pauly, M.V. and Y. Zeng (2004), ‘Adverse selection and the challenges to stand-alone prescription drug insurance’, Forum for Health Economics & Policy, 7, article 3, available at http://www.bepress.com/cgi/view content.cgi?article51051&context5fhep (accessed 1 November 2010).

  37. Philipson, T.J. and A.B. Jena (2006), ‘Surplus appropriation from R&D and health care technology assessment procedures’, NBER Working Paper, W12016, available at http://ssrn.com/abstract5881250 (accessed 15 April 2010).

  38. Reinhardt, U.E. (2001), ‘Perspectives on the pharmaceutical industry’, Health Affairs, 20 (5), 136–49.
    Paper not yet in RePEc: Add citation now
  39. Reinhardt, U.E. (2004), ‘An information infrastructure for the pharmaceutical market’, Health Affairs, 23 (1), 107–12.
    Paper not yet in RePEc: Add citation now

  40. Rothschild, M. and J.E. Stiglitz (1976), ‘Equilibrium in competitive insurance markets: an essay on the economics of imperfect information’, Quarterly Journal of Economics, 90 (4), 629–49.

  41. Scherer, F.M. (2001), ‘The link between gross profits and pharmaceutical R&D spending’, Health Affairs, 20 (5), 216–20.
    Paper not yet in RePEc: Add citation now
  42. Sood, N., H. de Vries, I. Gutierrez, D.N. Lakdawalla and D.P. Goldman (2009), ‘The effect of regulation on pharmaceutical revenues: experience in nineteen countries’, Health Affairs, 28 (1), w125–w137.
    Paper not yet in RePEc: Add citation now
  43. Soumerai, S.B., J. Avorn, D. Ross-Degnan and S. Gortmaker (1987), ‘Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity’, New England Journal of Medicine, 317 (9), 550–6.
    Paper not yet in RePEc: Add citation now
  44. Soumerai, S.B., T.J. McLaughlin, D. Ross-Degnan, C.S. Casteris and P. Bollini (1994), ‘Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia’, New England Journal of Medicine, 331 (10), 650–5.
    Paper not yet in RePEc: Add citation now

  45. Stabile, M. (2001), ‘Private insurance subsidies and public health care markets: evidence from Canada’, Canadian Journal of Economics, 34 (4), 921–42.

  46. Tamblyn, R., R. Laprise, J.A. Hanley, M. Abrahamowicz, S. Scott, N. Mayo, J. Hurley, R. Grad, E. Latimer, R. Perreault, P. McLeod, A. Huang, P. Larochelle and L. Mallet (2001), ‘Adverse events associated with prescription drug cost-sharing among poor and elderly persons’, Journal of the American Medical Association, 285 (4), 421–9.
    Paper not yet in RePEc: Add citation now

  47. Yin, W. (2008), ‘Market incentives and pharmaceutical innovation’, Journal of Health Economics, 27 (4), 1060–77.

  48. Zeckhauser, R.J. (1970), ‘Medical insurance: a case study of the tradeoff between risk spreading and appropriate incentives’, Journal of Economic Theory, 2 (1), 10–26.

Cocites

Documents in RePEc which have cited the same bibliography

  1. Medical, transportation and spiritual out-of-pocket health expenditure on outpatient and inpatient visits in Bhutan. (2021). Phuntsho, Sonam ; Herberholz, Chantal.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:273:y:2021:i:c:s027795362100112x.

    Full description at Econpapers || Download paper

  2. Fractional order statistic approximation for nonparametric conditional quantile inference. (2017). Kaplan, David ; Goldman, Matt.
    In: Journal of Econometrics.
    RePEc:eee:econom:v:196:y:2017:i:2:p:331-346.

    Full description at Econpapers || Download paper

  3. Fractional order statistic approximation for nonparametric conditional quantile inference. (2016). Kaplan, David ; Goldman, Matt.
    In: Working Papers.
    RePEc:umc:wpaper:1502.

    Full description at Econpapers || Download paper

  4. Fractional order statistic approximation for nonparametric conditional quantile inference. (2016). Kaplan, David ; Goldman, Matt.
    In: Papers.
    RePEc:arx:papers:1609.09035.

    Full description at Econpapers || Download paper

  5. The financial burden of out of pocket prescription drug expenses in Canada. (2015). Al-Khatib, Naser ; Lynch, Tom ; Wu, Xiaojing ; Caldbick, Sam ; Farag, Marwa ; Andkhoie, Mustafa .
    In: International Journal of Health Economics and Management.
    RePEc:kap:ijhcfe:v:15:y:2015:i:3:p:329-338.

    Full description at Econpapers || Download paper

  6. Mandatory universal drug plan, access to health care and health: Evidence from Canada. (2015). Sweetman, Arthur ; Hurley, Jeremiah ; Wang, Chao ; Li, Qing.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:44:y:2015:i:c:p:80-96.

    Full description at Econpapers || Download paper

  7. INCOME AND THE USE OF PRESCRIPTION DRUGS FOR NEAR RETIREMENT INDIVIDUALS. (2014). Leth-Petersen, Søren ; LethPetersen, Soren ; Skipper, Niels.
    In: Health Economics.
    RePEc:wly:hlthec:v:23:y:2014:i:3:p:314-331.

    Full description at Econpapers || Download paper

  8. The Changing Role of Government in Financing Health Care: An International Perspective. (2014). Stabile, Mark ; Thomson, Sarah.
    In: Sciences Po publications.
    RePEc:spo:wpmain:info:hdl:2441/3ihldo33ik9ee94procjtfki5f.

    Full description at Econpapers || Download paper

  9. The Changing Role of Government in Financing Health Care: An International Perspective. (2014). Thomson, Sarah ; Stabile, Mark.
    In: Working Papers.
    RePEc:hal:wpaper:hal-03460310.

    Full description at Econpapers || Download paper

  10. The Changing Role of Government in Financing Health Care: An International Perspective. (2014). Stabile, Mark ; Thomson, Sarah.
    In: Journal of Economic Literature.
    RePEc:aea:jeclit:v:52:y:2014:i:2:p:480-518.

    Full description at Econpapers || Download paper

  11. Impact of healthcare reforms on out-of-pocket health expenditures in Turkey for public insurees. (2012). Erus, Burcay ; Aktakke, Nazli.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:13:y:2012:i:3:p:337-346.

    Full description at Econpapers || Download paper

  12. Prescription Drug Insurance and Reimbursement. (2012). Grootendorst, Paul .
    In: Chapters.
    RePEc:elg:eechap:14021_11.

    Full description at Econpapers || Download paper

  13. Impact of Healthcare Reforms on Out-of-Pocket Health Expenditures in Turkey for Public Insurees. (2010). Erus, Buray .
    In: Working Papers.
    RePEc:erg:wpaper:544.

    Full description at Econpapers || Download paper

  14. Confidence Intervals for Estimates of Elasticities. (2008). Slottje, Daniel ; Lye, Jeanette ; Hirschberg, Joseph.
    In: Department of Economics - Working Papers Series.
    RePEc:mlb:wpaper:1053.

    Full description at Econpapers || Download paper

  15. Inferential methods for elasticity estimates. (2008). Slottje, Daniel ; Lye, Jeanette ; Hirschberg, Joseph.
    In: Journal of Econometrics.
    RePEc:eee:econom:v:147:y:2008:i:2:p:299-315.

    Full description at Econpapers || Download paper

  16. Equity in Pharmaceutical Utilization in Ontario: A Cross Section and Over Time Analysis. (2007). ZHONG, HAI.
    In: University of Western Ontario, Economic Policy Research Institute Working Papers.
    RePEc:uwo:epuwoc:20071.

    Full description at Econpapers || Download paper

  17. Development of a capitation scale for IDF career soldiers in Israel. (2007). Shmueli, Amir ; Weiss, Yossi ; Cohen, Yossi ; Magnezi, Racheli.
    In: Health Policy.
    RePEc:eee:hepoli:v:80:y:2007:i:3:p:459-464.

    Full description at Econpapers || Download paper

  18. Equity in Pharmaceutical Utilization in Ontario: A Cross-Section and Over Time Analysis. (2007). ZHONG, HAI.
    In: Canadian Public Policy.
    RePEc:cpp:issued:v:33:y:2007:i:4:p:487-508.

    Full description at Econpapers || Download paper

  19. Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients. (2006). Rossetti, Claudio ; Peracchi, Franco ; Depalo, Domenico ; Atella, Vincenzo ; de Palo, Domenico.
    In: Health Economics.
    RePEc:wly:hlthec:v:15:y:2006:i:9:p:875-892.

    Full description at Econpapers || Download paper

  20. Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?. (2004). Berndt, Ernst R. ; Crown, William H. ; Witt, Whitney P. ; Finkelstein, Stan N. ; Baser, Onur ; Haver, Kenan E. ; Maguire, Jonathan .
    In: NBER Chapters.
    RePEc:nbr:nberch:9871.

    Full description at Econpapers || Download paper

  21. Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?. (2003). Baser, Onur ; Berndt, Ernst R. ; Crown, William H. ; Witt, Whitney P. ; Finkelstein, Stan N. ; et. al., .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:10062.

    Full description at Econpapers || Download paper

  22. National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirbys Recommendations?. (2003). Veall, Michael ; Grootendorst, Paul ; Crossley, Thomas.
    In: Social and Economic Dimensions of an Aging Population Research Papers.
    RePEc:mcm:sedapp:105.

    Full description at Econpapers || Download paper

  23. National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirbys Recommendations?. (2003). Veall, Michael ; Grootendorst, Paul ; Crossley, Thomas.
    In: Quantitative Studies in Economics and Population Research Reports.
    RePEc:mcm:qseprr:385.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2024-12-26 09:52:49 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.